Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
These medications are based on modified human GLP-1 sequences, though their development was inspired by the proof-of-concept established through the exendin-4 discovery
In particular, GLP-1 receptor agonists such as semaglutide and the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide have demonstrated substantial efficacy for weight reduction in individuals with obesity
Batch number on the COA must match the batch number on the product label
Do not change any diabetes medicine without professional guidance
Months 6 to 12: The SURMOUNT-5 trial published in the NEJM in 2025 found tirzepatide produced 20.2% body weight loss compared to 13.7% for semaglutide over 72 weeks in patients with obesity
Carnitine may be involved because its concentration in tissues declines with age, which deteriorates the mitochondrial membrane
)
US$ 27.72
US$ 24.82
US$ 20.05
